Abstract: The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenström's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.
Type:
Grant
Filed:
August 9, 2006
Date of Patent:
August 19, 2014
Assignees:
Ares Trading S.A., Zymogenetics, Inc.
Inventors:
Herve Broly, Arnaud Ythier, Eric Sievers
Abstract: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.
Type:
Grant
Filed:
May 15, 2007
Date of Patent:
July 22, 2014
Assignees:
Zymogenetics, Inc., Ares Trading S.A.
Inventors:
Herve Broly, Jennifer Visich, Ivan Nestorov, Sharon Busby, Jane Gross
Abstract: The invention relates to the field of pharmaceutical formulations. More particularly it is directed to freeze-dried formulations of Fibroblast Growth Factor 18 (FGF-18) compound and to methods of producing such formulations. The freeze-dried formulations according to the invention are stable upon storage for an appropriate period of time. They can be used, after reconstitution, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
Abstract: The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26,000 and 40,000 g/mol, grafted with alpha-tocopherol substituents, the average molar grafting ratio being 4.5-5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time.
Type:
Application
Filed:
May 16, 2012
Publication date:
April 17, 2014
Applicant:
ARES TRADING S.A.
Inventors:
Daniel Leblanc, Evert Nicolaas Lamme, Helen Gabriela Baldascini, Joel Richard, Frederic Checot, You-Ping Chan, Roger Kravtzoff, Gauthier Pouliquen
Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
Type:
Application
Filed:
May 10, 2012
Publication date:
March 27, 2014
Applicant:
ARES TRADING S.A.
Inventors:
Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
Abstract: The invention relates to a method for purifying a glycoprotein, preferably FSH or a FSH mutant, comprising the steps of subjecting a liquid containing FSH or a FSH mutant to: (1) a dye affinity chromatography; (2) a weak anion exchange chromatography; (3) a hydrophobic interaction chromatography; and (4) a strong anion exchange chromatography; which may be carried out in any order.
Type:
Grant
Filed:
December 6, 2006
Date of Patent:
December 10, 2013
Assignee:
Ares Trading S.A.
Inventors:
Thierry Ziegler, Mara Rossi, Antonello Datola, Sabrina Fiumi
Abstract: The invention relates to a process for reducing the concentration of free Fc-moieties in a fluid comprising an Fc-containing protein comprising a cation exchange chromatography step.
Abstract: The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
Abstract: The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
Abstract: A medication delivery device includes a housing, a door coupled to the housing and moveable between a closed position and an open position. The door permits insertion of a medication container, containing liquid medication, into the housing in the open position. A door opening mechanism is coupled to the door. A push member is axially moveable between a retracted position and a non-retracted position and located external to the medication container. The push member enters the medication container and pushes the liquid medication out of the medication container. A lock mechanism is coupled to the door opening mechanism and prevents opening of the door when the push member is in the non-retracted position inside the medication container, wherein the lock mechanism automatically unlocks the door opening mechanism when the push member is in the retracted position.
Type:
Grant
Filed:
April 28, 2011
Date of Patent:
February 19, 2013
Assignee:
Ares Trading S.A.
Inventors:
Vincent Pongpairochana, Timothy John MacLean, Robert Prasser, Gerhard Lauchard, Werner Wurmbauer, Gerhard Kogler
Abstract: A process and a device for retaining polarizable target-particles from a fluid suspension of polarizable target-particles comprising the steps of pumping that suspension into a vertical or inclined channel and applying an alternating electric field inducing a negative dielectrophoretic force on the target-particles, the force being sufficient to push them a distance of at least or about 25 m from the surface of an electrode-bearing wall, thereby creating an upward-moving clarified fluid zone in the vicinity of that wall and a downward-moving target-particle containing fluid zone at a distance from that wall.
Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
Type:
Grant
Filed:
March 4, 2010
Date of Patent:
December 11, 2012
Assignee:
Ares Trading S.A.
Inventors:
Nicole Deglon, Patrick Aebischer, Jean-Charles Bensadoun
Abstract: A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, a surfactant, an isotonicity agent and an antioxidant. Preferably the interferon is human recombinant IFN-beta.
Type:
Grant
Filed:
April 29, 2004
Date of Patent:
November 13, 2012
Assignee:
Ares Trading S.A.
Inventors:
Fabrizio Samaritani, Alessandra Del Rio
Abstract: An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition including an anilinopyrimidine derivative of Formula (I) and a pharmaceutically acceptable excipient selected from the group consisting of polyethylene glycol, a glyceryl ester of capric acid or a mixture thereof. The liquid fill composition is formulated in a hard gelatin capsules and can be used for the preparation of a medicament for the treatment of cancer in particular AML.
Abstract: The invention relates to a process for the manufacturing of a protein, such as growth hormone, in mammalian cells cultured in a serum-free medium (medium free of components derived from animal serum). The medium contains cobalt and, optionally, cadmium or cyclodextrin.
Type:
Grant
Filed:
April 16, 2010
Date of Patent:
September 25, 2012
Assignee:
Ares Trading S.A.
Inventors:
Jose Casatorres Hernandez, Carlos Martin Piera
Abstract: Proteins (INSP141, INSP142, INSP143, and INSP144) identified as anthrax receptor-like proteins containing von Willebrand factor A (vWFA) and Anthrax receptor extracellular (ANT_IG) domains and the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease are described.
Type:
Grant
Filed:
October 28, 2005
Date of Patent:
July 17, 2012
Assignee:
Ares Trading S.A.
Inventors:
Mark Douglas Davies, David Michalovich, Melanie Yorke, Christine Power
Abstract: The invention relates to a process for the production of purified IL-18 binding protein (IL-18BP) from a fluid comprising affinity chromatography.
Type:
Grant
Filed:
June 8, 2006
Date of Patent:
July 10, 2012
Assignee:
Ares Trading S.A.
Inventors:
Claire Le Strat, Frederic Meuwly, Pierre Wenger, Pascal Valax, Gianni Baer, Henri Kornmann